128 tracked 13F filers disclose a position in JBIO as of the latest SEC 13F filings, a combined $898.2M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $99.6M | 7.1M | ▲+2.8% Added · +191K sh | Q1 2026 | |
| 2 | Fairmount Funds Management LLC | $101.2M | 4.6M | —Held | Q2 2026 | |
| 3 | RA CAPITAL MANAGEMENT, L.P. | $51.6M | 3.7M | —Held | Q1 2026 | |
| 4 | Venrock Adviser, LLC | $45.2M | 3.2M | —Held | Q1 2026 | |
| 5 | Janus Henderson Group Ltd. | $43.6M | 3.1M | ▲New +3.1M sh | Q1 2026 | |
| 6 | Bellevue Group AG | $67.9M | 3.1M | ▼−13% Reduced · −444K sh | Q2 2026 | |
| 7 | STATE STREET CORP | $51.9M | 2.3M | ▲+256% Added · +1.7M sh | Q2 2026 | |
| 8 | BlackRock, Inc. | $32.5M | 2.3M | ▼−19% Reduced · −556K sh | Q1 2026 | |
| 9 | Polar Capital Holdings Plc | $41.0M | 1.8M | ▲New +1.8M sh | Q2 2026 | |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | $25.2M | 1.8M | →First observed position No prior filed position | Q1 2026 | |
| 11 | BAKER BROS. ADVISORS LP | $23.1M | 1.6M | —Held | Q1 2026 | |
| 12 | Remedium Capital Partners, LLC | $35.1M | 1.6M | —Held | Q2 2026 | |
| 13 | Soleus Capital Management, L.P. | $34.5M | 1.6M | ▲+95% Added · +754K sh | Q2 2026 | |
| 14 | Versant Venture Management, LLC | $23.5M | 1.5M | —Held | Q4 2025 | |
| 15 | Avidity Partners Management LP | $19.7M | 1.4M | —Held | Q1 2026 | |
| 16 | ACORN CAPITAL ADVISORS, LLC | $21.9M | 987K | ▲+25% Added · +200K sh | Q2 2026 | |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | $21.9M | 985K | ▲+20% Added · +163K sh | Q2 2026 | |
| 18 | Samsara BioCapital, LLC | $13.6M | 969K | —Held | Q1 2026 | |
| 19 | GREAT POINT PARTNERS LLC | $13.6M | 964K | ▲+20% Added · +158K sh | Q1 2026 | |
| 20 | MARSHALL WACE, LLP | $13.3M | 945K | ▲+7.9% Added · +70K sh | Q1 2026 | |
| 21 | Aberdeen Group plc | $12.2M | 867K | —Held | Q1 2026 | |
| 22 | Affinity Asset Advisors, LLC | $9.0M | 640K | ▼−10% Reduced · −75K sh | Q1 2026 | |
| 23 | Ikarian Capital, LLC | $7.2M | 512K | ▲+71% Added · +212K sh | Q1 2026 | |
| 24 | Opaleye Management Inc. | $6.0M | 428K | —Held | Q1 2026 | |
| 25 | BALYASNY ASSET MANAGEMENT L.P. | $5.7M | 402K | ▲New +402K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 19 funds opened a new position in JBIO and 25 added to an existing one, while 9 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| ELI LILLY & COLLY | 64 funds | $42.0B |
| BOSTON SCIENTIFIC CORPBSX | 61 funds | $7.3B |
| NVIDIA CORPNVDA | 60 funds | $211.0B |
| ALPHABET INC-CL AGOOGL | 60 funds | $76.1B |
| REVOLUTION MEDICINES INCRVMD | 60 funds | $3.4B |
| MICROSOFT CORPMSFT | 59 funds | $138.3B |
| AMAZON.COM INCAMZN | 59 funds | $99.1B |
| GILEAD SCIENCES INCGILD | 59 funds | $10.8B |
| META PLATFORMS INC-CLASS AMETA | 58 funds | $61.1B |
| JOHNSON & JOHNSONJNJ | 58 funds | $21.3B |
| MICRON TECHNOLOGY INCMU | 58 funds | $18.8B |
| ADVANCED MICRO DEVICESAMD | 58 funds | $18.7B |
Ranked by how many of JBIO's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| May 16, 2025 | Frohlich Tom | Chief Executive Officer, Director | Buy (P) | 6K | $44K |
Connected entities for JBIO
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/JBIO/capital-change-brief"
Use Arkolith's capital_change_brief for JBIO. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for JBIO. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.